Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)

News & Events

Investors, Press Releases

The Board of Directors approves the draft financial statements

Apr 27, 2021

The Board of Directors approves the draft financial statements and the consolidated financial statements as of 31 december 2020 (Courtesy English Translation) (Price Sensitive)

Last News & Events

Oct 2017 12

Philogen announces authorization from FDA of a pivotal registration trial in USA for the treatment of resectable melanoma

Aug 2017 25

Philogen announces research collaboration with Servier in the field of DNA-encoded chemistry

  • « Previous
  • 1
  • …
  • 94
  • 95
  • 96
  • 97
  • 98
  • …
  • 103
  • Next »

Privacy Policy / Cookie Policy

  Contacts

  • Follow
  • Follow

Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it